

**DRUGS COVERED UNDER THE
MEDICARE REPLACEMENT DRUG DEMONSTRATION**
(updated November 10, 2004)

| Demonstration Covered Indication | Drug/Biological—Compound Name (Brand Name) |
|--|---|
| Rheumatoid Arthritis | Adalimumab (Humira) |
| | Anakinra (Kineret) |
| | Etanercept (Enbrel) |
| Psoriatic Arthritis | Etanercept (Enbrel) |
| Multiple Sclerosis | Glatiramer acetate (Copaxone) |
| | Interferon beta –1a (Rebif, Avonex) |
| | Interferon beta –1b (Betaseron) |
| Post Menopausal Osteoporosis (patient must be homebound) | Calcitonin – nasal (Miacalcin – nasal) |
| | Risedronate (Actonel) |
| | Alendronate (Fosamax) |
| | Raloxifene hydrochlorid (Evista) |
| Pulmonary Hypertension | Bosentan (Tracleer) |
| Secondary Hyperparathyroidism | Doxercalciferol (Hectoral) |
| Paget's Disease | Alendronate (Fosamax) |
| | Risedronate (Actonel) |
| Hepatitis C | Pegylated interferon alfa-2a (Pegasys) |
| | Pegylated interferon alfa-2b (PEG-Intron) |
| CMV Retinitis | Valcyte (Valganciclovir) |
| Acromegaly | Pegvisomant (Somavert) |
| Anti-Cancer | |
| Cutaneous T-cell Lymphoma | Bexarotene (Targretin) |
| Non-small cell lung cancer | Gefitinib (Iressa) |
| Epithelial ovarian cancer | Altretamine (Hexalen) |
| Chronic Myelogenous Leukemia | Imatinib Mesylate (Gleevec) |
| GI Stromal Tumor | Imatinib Mesylate (Gleevec) |
| Multiple Myeloma | Thalidomide (Thalomid) |
| Breast Cancer | Hormonal therapy |
| Stage 2-4 only | Anastrozole (Arimidex) |
| | Exemestane (Aromasin) |
| | Letrozole (Femara) |
| | Tamoxifen (Nolvadex) |
| | Toremifene (Fareston) |
| Prophylactic agent to reduce ifosfamide-induced hemorrhagic cystitis | Mesna (Mesnex) |